Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

Group3 (G3) medulloblastoma (MB) is one of the deadliest forms of the disease for which novel treatment is desperately needed. Here we evaluate ribociclib, a highly selective CDK4/6 inhibitor, with gemcitabine in mouse and human G3MBs. Ribociclib central nervous system (CNS) penetration was assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Pribnow, Allison, Jonchere, Barbara, Liu, Jingjing, Smith, Kyle S., Campagne, Olivia, Xu, Ke, Robinson, Sarah, Patel, Yogesh, Onar-Thomas, Arzu, Wu, Gang, Stewart, Clinton F., Northcott, Paul A., Yu, Jiyang, Robinson, Giles W., Roussel, Martine F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578677/
https://www.ncbi.nlm.nih.gov/pubmed/35709750
http://dx.doi.org/10.1158/1535-7163.MCT-21-0598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578677/
https://www.ncbi.nlm.nih.gov/pubmed/35709750
http://dx.doi.org/10.1158/1535-7163.MCT-21-0598

Ejemplares similares